GNC is struggling. It hopes Ozempic can give it a boost

GNC, a struggling vitamin and supplement chain, plans to attract customers by targeting people taking GLP-1 drugs for weight loss. The company will introduce a dedicated section in its US stores, offering products tailored to individuals on GLP-1 medications. GNC is also training store employees on related side effects and stocking relevant items. Other businesses, including gyms and food companies, are also adjusting their strategies to cater to the rise in GLP-1 usage. The Danish pharmaceutical company Novo Nordisk is profiting from its GLP-1 products, with other major companies racing to enter the market. The use of GLP-1 drugs is expected to increase significantly, with an estimated 30 million people in the US taking them by 2030.